271 results for "study_type:"exome sequencing" AND repository:ega"

in 4.62 milliseconds.

• Whole-exome sequencing data from a phase 2 trial of dasatinib for patients with relapsed or refractory nodal T follicular helper cell lymphomas

  Whole-exome sequencing (WES) analysis data from tumor tissues of 14 patients with T follicular helper cell lymphomas enrolled in a phase 2 trial of dasatinib for relapsed or refractory nodal disease.

  Study EGAS50000001239

• Whole Exome sequencing of Baseline biopsies

  Whole exome sequencing of BAseline CHC-noHCC and CHC-HCC biopsies.

  Study EGAS50000001096

• Germline WES of serrated polyposis syndrome

  The serrated polyposis syndrome (SPS) is a disease with a mainly unknown inherited genetic basis characterized by the presence of multiple and/or large serrated polyps in the colon and a higher associated risk for colorectal cancer (CRC). The objective of the present study was to identify new SPS/CRC germline predisposition genes by using whole-exome sequencing in two affected SPS patients from the same family.

  Study EGAS50000000765

• TRACERx NSCLC - Whole exome multiregion sequencing data

  Study EGAS00001006494

• Mechanisms of resistance to pembrolizumab treatment in classical Hodgkin Lymphoma

  In this project we are applying whole exome sequencing (WES) on plasma-derived ctDNA samples to identify mutations that drive resistance to pembrolizumab treatment in classical Hodgkin Lymphoma

  Study EGAS50000001985

• Familial Melanoma Sequencing

  In this experiment we have sequenced the exome of 15 individuals from eight families who have familial melanoma. By sequencing the exome we hope to be able to identify new genes that are associated with this disease.

  Study EGAS00001000017

• Spatial atlas of diffuse large B-cell lymphoma

  We leveraged highly multiplexed, single-cell–resolution spatial transcriptomics, bulk RNA sequencing, and tumor–germline paired whole-exome sequencing to profile 465 diffuse large B-cell lymphoma (DLBCL) tumors and define the assembly of 60 lymphoma microenvironment (LME) cell subsets and 5 tumor B cell states into conserved spatial niches and communities that resemble non-malignant lymphoid architecture. Three distinct LME-enriched communities were assembled from combinations of niches and reflected recently described LME archetypes with conserved spatial biology. Tumor B cells were enriched in three B communities harboring distinct, developmentally linked, transcriptional states associated with divergent cell-cell communication (CCC) pathways. Intratumoral heterogeneity in B communities was pervasive across patients and largely unlinked with molecular subtype. Combinations of B communities, rather than single states, were associated with patient outcome, implicating microenvironment-associated tumor B cell transcriptional plasticity in the biology and clinical behavior of DLBCL.

  Study EGAS50000002036

• Whole Exome Sequencing

  ASTEROID Phase 1 trial of combination IAP inhibitor ASTX660 and pembrolizumab. Matched tumour biopsies and PBMCs were sequenced.

  Study EGAS50000002044

• Analysis of Somatic Mutations from Liquid Biopsy-Derived cfDNA in Advanced Cancers

  This study aims to identify somatic mutations and characterize potential neoantigens for immunotherapeutic targeting using paired whole-exome sequencing (WES) of germline DNA and plasma-derived circulating cell-free DNA (cfDNA) from patients with advanced-stage cancers.

  Study EGAS50000001169

• Exome sequencing

  Exome sequencing of patient tumor biopsy, cfDNA and normal PBMC DNA samples

  Study EGAS50000001170